By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Business of developing innovative targeted and immune- modulating cancer therapies5M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States5M100.00%